Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation

Blood. 2020 Nov 5;136(19):2237-2240. doi: 10.1182/blood.2019004371.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage*
  • Female
  • Follow-Up Studies
  • Humans
  • Imatinib Mesylate / administration & dosage*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Middle Aged
  • Prognosis
  • Survival Rate
  • Tumor Burden / drug effects*
  • Withholding Treatment / statistics & numerical data*
  • Young Adult

Substances

  • Antineoplastic Agents
  • Imatinib Mesylate